Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly

If you suffered losses exceeding $75,000 in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

NEW YORK, Dec. 18, 2024 – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) and reminds investors of the February 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

The investigation is focusing on whether Cassava and certain of its officers and/or directors have violated federal securities laws. On August 16, 2024, Cassava disclosed negative results from its Alzheimer’s disease treatment study. Following this news, Cassava’s stock price fell significantly, causing harm to investors.

Impact on Investors:

Investors who suffered losses exceeding $75,000 in Cassava may have legal options to recover their losses. By contacting Faruqi & Faruqi partner Josh Wilson, investors can discuss their rights and potential next steps in seeking compensation for their losses.

Impact on the World:

The investigation and potential securities class action against Cassava could have broader implications for the pharmaceutical and biotech industry. Investors may become more cautious in investing in companies conducting clinical trials, leading to increased scrutiny and regulation in the sector.

Conclusion:

Investors who suffered losses in Cassava should take immediate action to protect their legal rights and explore their options for recovery. The outcome of the investigation and class action could have far-reaching effects on both investors and the pharmaceutical industry as a whole.